Intensive Care Unit, Polymyxin B, Tigecycline
Conditions
Brief summary
The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin B admitted to the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from 2017 to 2021 were included. To analyze the therapeutic effect of tigecycline-based or polymyxin B-based antibiotic regimens and their effect on the prognosis of patients, and to conduct subgroup analysis.
Detailed description
The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin B admitted to the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from 2017 to 2021 were included. The four hospitals included the 1st-3th XiangYa Hospitals and Hunan Provincial People's Hospital. Organize the data.Patients with a course of treatment \< 4 days and shedding were excluded.To analyze the therapeutic effect of tigecycline-based or polymyxin B-based antibiotic regimens and their effect on the prognosis of patients, and to conduct subgroup analysis. The chi-square test was used for the counting data, and the Mann-Whitney U test or Kruskal-Wallis H test was used for the measurement data. The significance value was adjusted by Bonferroni correction method for multiple tests, and the P was tested on both sides,P\>0.05.
Interventions
None listed
Sponsors
Xiangya Hospital of Central South University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No
Inclusion criteria
* ICU patients receiving tigecycline or polymyxin B treatment; * Age 14-95, gender unlimited; * there are clear infections and strains; * The patient and/or his/her family agree to sign the informed consent voluntarily.
Exclusion criteria
* Patients with treatment of less than 4 days; * patients with abscission; * Pregnant patients; * Patients with age \< 14 years or \> 95 years.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| hospital mortality rate | up to hospital discharge or die in hospital, up to 48 weeks(estimation). | Patients die in hospital or abandon treatment due to poor prognosis in hospital after treatment of tigecycline or polymyxin B |
| 30d mortality rate | up to the 30th day of the treatment of tigecycline or polymyxin B | Patients die after treatment of tigecycline or polymyxin B |
| Bacterial clearance rate | from the first day of the treatment of tigecycline or polymyxin B until to the end day, up to 8 weeks (estimation). | Bacterial clearance during treatment of tigecycline or polymyxin B |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| serum creatinine | at the end day of the treatment of tigecycline or polymyxin B, up to 8 weeks (estimation). | serum creatinine at the end day of the treatment of tigecycline or polymyxin B |
| The length of hospital stay | up to hospital discharge or die in hospital, up to 48 weeks (estimation). | The length of hospital stay,days |
| VA days | up to hospital discharge or die in hospital, up to 48 weeks (estimation). | the total days with vasoactive agent |
| MV days | up to hospital discharge or die in hospital, up to 48 weeks (estimation). | the total days with mechanical ventilation |
| The length of ICU stay | up to hospital discharge or die in hospital, up to 24 weeks (estimation). | The length of ICU stay |
| Hospitalization Cost | up to hospital discharge or die in hospital, up to 48 weeks (estimation). | total Hospitalization Cost |
Countries
China
Contacts
Primary ContactShuangping Zhao
Outcome results
None listed